{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:19:20Z","timestamp":1775071160439,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jaad.2016.02.1240","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T06:16:34Z","timestamp":1484288194000},"page":"191-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Prevention and management of glucocorticoid-induced side effects: A comprehensive review"],"prefix":"10.1016","volume":"76","author":[{"given":"Avrom","family":"Caplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Fett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.02.1240_bib1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of pneumocystic pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2016.02.1240_bib2","first-page":"CD005590","article-title":"Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"10","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2016.02.1240_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2009.11.588","article-title":"Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions","volume":"63","author":"Lehman","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.02.1240_bib4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2009.07.042","article-title":"Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications","volume":"62","author":"Gerhart","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.02.1240_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1378\/chest.118.3.704","article-title":"Management and outcome patters for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2016.02.1240_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"issue":"4 part 2","key":"10.1016\/j.jaad.2016.02.1240_bib7","first-page":"S221","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2016.02.1240_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/0003-4819-84-3-261","article-title":"The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population","volume":"84","author":"Schatz","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2016.02.1240_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1378\/chest.38.1.51","article-title":"Reversion and reconversion rate of tuberculin skin test reactions in correlation with use of prednisone","volume":"38","author":"Bovornkitti","year":"1960","journal-title":"Dis Chest"},{"key":"10.1016\/j.jaad.2016.02.1240_bib10","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2016.02.1240_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2016.02.1240_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/thoraxjnl-2013-203247","article-title":"How should I interpret an interferon gamma release assay result for tuberculosis infection?","volume":"68","author":"Abubakar","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jaad.2016.02.1240_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2016.02.1240_bib14","first-page":"498","article-title":"Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results","volume":"12","author":"Menzies","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jaad.2016.02.1240_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.trstmh.2008.01.020","article-title":"Strongyloides hyperinfection syndrome: an emerging global infectious disease","volume":"102","author":"Marcos","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jaad.2016.02.1240_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s10096-005-0070-2","article-title":"Disseminated strongyloidiasis: a retrospective study of clinical course and outcome","volume":"25","author":"Lam","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jaad.2016.02.1240_bib17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.trstmh.2007.05.021","article-title":"Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases","volume":"101","author":"Ghosh","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jaad.2016.02.1240_bib18","unstructured":"Centers for Disease Control and Prevention website. Parasites\u00a0\u2013 Strongyloidiasis. Available at: http:\/\/www.cdc.gov\/parasites\/strongyloides\/. Accessed June 30, 2014."},{"key":"10.1016\/j.jaad.2016.02.1240_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-7961-4-8","article-title":"Intestinal strongyloidiasis and hyperinfection syndrome","volume":"4","author":"Vadlamudi","year":"2006","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jaad.2016.02.1240_bib20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaad.2009.09.037","article-title":"Disseminated Strongyloides stercoralis: hyperinfection during medical immunosuppression","volume":"63","author":"Basile","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.02.1240_bib21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ejim.2009.09.001","article-title":"Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view","volume":"20","author":"Santiago","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaad.2016.02.1240_bib22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.33321\/cdi.2003.27.87","article-title":"Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory","volume":"27","author":"Davis","year":"2003","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.jaad.2016.02.1240_bib23","first-page":"587","article-title":"Rheumatological patients undergoing immunosuppressive treatments and parasitic diseases: a review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections","volume":"32","author":"Fabiani","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2016.02.1240_bib24","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.ijid.2009.02.009","article-title":"Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases","volume":"13","author":"Peters","year":"2009","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jaad.2016.02.1240_bib25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/QCO.0b013e3283551dbd","article-title":"Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis","volume":"25","author":"Mejia","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jaad.2016.02.1240_bib26","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2016.02.1240_bib27","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1440-1843.2010.01822.x","article-title":"Systemic corticosteroid and reactivation of chronic hepatitis B","volume":"15","author":"Lai","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.jaad.2016.02.1240_bib28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1440-1843.2010.01798.x","article-title":"Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids","volume":"15","author":"Kim","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.jaad.2016.02.1240_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2169\/internalmedicine.31.208","article-title":"Two fatal cases of hepatitis B virus carriers after corticosteroid therapy for bronchial asthma","volume":"31","author":"Koga","year":"1992","journal-title":"Intern Med"},{"key":"10.1016\/j.jaad.2016.02.1240_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1055\/s-2007-1024398","article-title":"Fatal liver failure after corticosteroid treatment of a hepatitis B virus carrier","volume":"124","author":"Hammond","year":"1999","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jaad.2016.02.1240_bib31","first-page":"A3710","article-title":"Reactivation of hepatitis B infection due to glucocorticoids","volume":"155","author":"Ramsoekh","year":"2011","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.jaad.2016.02.1240_bib32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(80)90442-0","article-title":"Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis","volume":"2","author":"Sagnelli","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.02.1240_bib33","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0016-5085(81)80002-9","article-title":"Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B","volume":"81","author":"Scullard","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2016.02.1240_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0168-8278(91)90946-9","article-title":"A randomized double-blind placebo-controlled trial of prednisolone therapy in HBeAg and HBV DNA positive Chinese patients with chronic active hepatitis B","volume":"12","author":"Lee","year":"1991","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2016.02.1240_bib35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2007.08058.x","article-title":"Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy","volume":"157","author":"Yang","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.02.1240_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/jmv.23889","article-title":"Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C?","volume":"86","author":"Romero Guti\u00e9rrez","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaad.2016.02.1240_bib37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0016-5085(94)90077-9","article-title":"Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C","volume":"107","author":"Fong","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2016.02.1240_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004836-200102000-00008","article-title":"Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial","volume":"32","author":"McHutchison","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jaad.2016.02.1240_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2016.02.1240_bib40","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.02.1240_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2466-11-59","article-title":"Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study","volume":"11","author":"Ernst","year":"2011","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaad.2016.02.1240_bib42","doi-asserted-by":"crossref","first-page":"E275","DOI":"10.1503\/cmaj.101137","article-title":"Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study","volume":"183","author":"Yang","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.jaad.2016.02.1240_bib43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/1346-8138.12175","article-title":"Infection in autoimmune\u00a0bullous diseases: a retrospective comparative study","volume":"40","author":"Lehman","year":"2013","journal-title":"J Dermatol"},{"issue":"suppl 4","key":"10.1016\/j.jaad.2016.02.1240_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/ajt.12122","article-title":"AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation","volume":"13","author":"Danziger-Isakov","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaad.2016.02.1240_bib45","first-page":"1","article-title":"General recommendations on immunization \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"National Center for Immunization and Respiratory Diseases","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2016.02.1240_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00296-013-2907-9","article-title":"Comparison of national clinical practice guidelines and recommendations on vaccination of\u00a0adult patients with autoimmune rheumatic diseases","volume":"34","author":"Papadopoulou","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2016.02.1240_bib47","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2016.02.1240_bib48","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2016.02.1240_bib49","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.autrev.2010.12.003","volume":"10","author":"van Assen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2016.02.1240_bib50","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.02.1240_bib51","first-page":"110","article-title":"Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014","volume":"63","author":"Bridges","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2016.02.1240_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tmaid.2014.04.009","article-title":"The medically immunocompromised adult traveler and pre-travel counseling: Status quo 2014","volume":"12","author":"Askling","year":"2014","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.jaad.2016.02.1240_bib53","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/acr.22021","article-title":"Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study","volume":"65","author":"Kerneis","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2016.02.1240_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1399-3062.2011.00686.x","article-title":"Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study","volume":"14","author":"Azevedo","year":"2012","journal-title":"Transplant Infect Dis"},{"key":"10.1016\/j.jaad.2016.02.1240_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbmt.2013.11.013","article-title":"Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients","volume":"20","author":"Issa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2016.02.1240_bib56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/INF.0b013e3181fe0868","article-title":"The\u00a0immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children","volume":"30","author":"Taweesith","year":"2011","journal-title":"Pediatr Infect Dis J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216300421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216300421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:41:28Z","timestamp":1759272088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216300421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0190962216300421"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1240","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and management of glucocorticoid-induced side effects: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(16)31259-2","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc. Published by Elsevier. All rights reserved.","name":"copyright","label":"Copyright"}]}}